Table 1 Patients characteristics and main results.
Patients | General series | TACE exclusive | TACE non exclusive | TACE exclusive lipiodol | TACE exclusive microspheres |
|---|---|---|---|---|---|
n = 150 | n = 82 | n = 68 | n = 50 | n = 32 | |
Median Age (range) | 69 (40-89) | 72 (41-89) | 66 (40-84) | 74 (42-89) | 68 (41-79) |
OS months (range) | 32 (3-124) | 30 (3-91) | 32 (3-124) | 46 (3-87) | 14 (3-91) |
TTP months (range) | 24 (1-64) | 26 (1-64) | 24 (1-52) | 32 (1-64) | 13 (1-28) |
Gender (%) | |||||
male | 122 (81) | 65 (79) | 57 (84) | 36 (79) | 29 (91) |
female | 28 (19) | 17 (21) | 11 (16) | 14 (21) | 3 (9) |
Patients undergoing TACE (%) | |||||
TACE exclusive | 82 (55) | ||||
TACE non exclusive | 68 (45) | ||||
Type of TACE (%) | |||||
TACE | 87 (58) | 50 (61) | 37 (54) | ||
pTACE | 63 (42) | 32 (39) | 31 (46) | ||
OS months (Type of TACE) (range) | |||||
TACE | 46 (3-124) | ||||
pTACE | 19 (3-91) | ||||
TTP months (Type of TACE) (range) | |||||
TACE | 30 (1-64) | ||||
pTACE | 16 (1-38) |